By inhibiting snail signaling and miR-23a-3p, osthole suppresses the EMT-mediated metastatic ability in prostate cancer

Oncotarget

Volumn 6, Issue 25, 2015, Pages 21120-21136

  Wen, Yu Ching ^a,b   Lee, Wei Jiunn ^b   Tan, Peng ^a   Yang, Shun Fa ^c,d   Hsiao, Michael ^e   Lee, Liang Ming ^b   Chien, Ming Hsien ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

EMT; MiR 23a 3p; Osthole; Prostate cancer; Snail

Indexed keywords

MICRORNA; MICRORNA 23A 3P; MITOGEN ACTIVATED PROTEIN KINASE; OSTHOLE; PROTEIN KINASE B; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; 3' UNTRANSLATED REGION; CADHERIN; COUMARIN DERIVATIVE; MIRN23 MICRORNA, HUMAN; TRANSCRIPTION FACTOR;

3' UNTRANSLATED REGION; ANDROGEN INDEPENDENT PROSTATE CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DISEASE COURSE; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; PATHOLOGY; PROSTATIC NEOPLASMS; REPORTER GENE; SCID MOUSE; TUMOR CELL LINE; WOUND HEALING;

3' UNTRANSLATED REGIONS; ANIMALS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COUMARINS; DISEASE PROGRESSION; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; MALE; MICE; MICE, SCID; MICRORNAS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; WOUND HEALING;

EID: 84940758624     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4229     Document Type: Article

References (54)

1. Denmeade SR and Isaacs JT. Development of prostate cancer treatment: the good news. Prostate. 2004; 58: 211-224.
2. Denmeade SR and Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002; 2: 389-396.
3. Aquilina JW, Lipsky JJ and Bostwick DG. Androgen deprivation as a strategy for prostate cancer chemoprevention. J Natl Cancer Inst. 1997; 89: 689-696.
4. Singal R, Ramachandran K, Gordian E, Quintero C, Zhao W and Reis IM. Phase I/II Study of Azacitidine, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy. Clin Genitourin Cancer. 2015; 13:22-31.
5. Kumar R, Srinivasan S, Koduru S, Pahari P, Rohr J and Kyprianou N. Damodaran, C. Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells. Cancer Prev Res (Phila). 2009; 2: 234-243.
6. Zhou C, Ling MT, Kin-Wah Lee T, Man K, Wang X and Wong YC. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett. 2006; 233: 36-47.
7. Basler JW and Piazza GA. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol. 2004; 171: S59-62; discussion S62-53.
8. Osanto S, van Poppel H and Burggraaf J. Tasquinimod: a novel drug in advanced prostate cancer. Future Oncol. 2013; 9: 1271-1281.
9. Taichman RS, Loberg RD, Mehra R and Pienta KJ. The evolving biology and treatment of prostate cancer. J Clin Invest. 2007; 117: 2351-2361.
10. Tomaskovic-Crook E, Thompson EW and Thiery JP. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res. 2009; 11: 213.
11. Zeisberg M and Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009; 119: 1429-1437.
12. Keitel U, Scheel C and Dobbelstein M. Overcoming EMT-driven therapeutic resistance by BH3 mimetics. Oncoscience. 2014; 1: 706-708.
13. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000; 2: 76-83.
14. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 2002; 3: 155-166.
15. Argast GM, Krueger JS, Thomson S, Sujka-Kwok I, Carey K, Silva S, O'Connor M, Mercado P, Mulford IJ, Young GD, Sennello R, Wild R, Pachter JA et al. Inducible expression of TGFbeta, snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model. Clin Exp Metastasis. 2011; 28: 593-614.
16. Blechschmidt K, Kremmer E, Hollweck R, Mylonas I, Hofler H, Kremer M and Becker K F. The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagn Mol Pathol. 2007; 16: 222-228.
17. Peiro S, Escriva M, Puig I, Barbera MJ, Dave N, Herranz N, Larriba MJ, Takkunen M, Franci C, Munoz A, Virtanen I, Baulida J and Garcia de Herreros A. Snail1 transcriptional repressor binds to its own promoter and controls its expression. Nucleic Acids Res. 2006; 34: 2077-2084.
18. Emadi Baygi M, Soheili ZS, Schmitz I, Sameie S and Schulz WA. Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines. Cell Biol Toxicol. 2010; 26: 553-567.
19. Ambros V. The functions of animal microRNAs. Nature. 2004; 431: 350-355.
20. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL,Yanaihara N, Lanza GA et al. microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103: 2257-2261.
21. Cao M, Seike M, Soeno C, Mizutani H, Kitamura K, Minegishi Y, Noro R, Yoshimura A, Cai L and Gemma A. MiR-23a regulates TGF-beta-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol. 2012; 41: 869-875.
22. Zhang J, Shen C, Wang L, Ma Q, Xia P, Qi M, Yang M and Han B. Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: Involvement of the tumor suppressor miR30a and its target gene SOX4. Biochem Biophys Res Commun. 2014; 452: 746-752.
23. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008; 10: 202-210.
24. Nicoloso MS, Spizzo R, Shimizu M, Rossi S and Calin GA. MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009; 9: 293-302.
25. Ninio-Many L, Grossman H, Levi M, Zilber S, Tsarfaty I, Shomron N, Tuvar A, Chuderland D, Stemmer SM, Ben-Aharon I and Shalgi R. MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells. Oncoscience. 2014; 1: 250-261.
26. Ding Y, Lu X, Hu X, Ma J and Ding H. Osthole inhibits proliferation and induces apoptosis in human osteosarcoma cells. Int J Clin Pharmacol Ther. 2014; 52: 112-117.
27. Zhang L, Jiang G, Yao F, He Y, Liang G, Zhang Y, Hu B, Wu Y, Li Y and Liu H. Growth inhibition and apoptosis induced by osthole, a natural coumarin, in hepatocellular carcinoma. PLoS One. 2012; 7: e37865.
28. Kao SJ, Su JL, Chen CK, Yu MC, Bai KJ, Chang JH, Bien MY, Yang SF and Chien MH. Osthole inhibits the invasive ability of human lung adenocarcinoma cells via suppression of NF-kappaB-mediated matrix metalloproteinase-9 expression. Toxicol Appl Pharmacol. 2012; 261: 105-115.
29. Thornes RD, Daly L, Lynch G, Breslin B, Browne H, Browne HY, Corrigan T, Daly P, Edwards G, Gaffney E et al. Treatment with coumarin to prevent or delay recurrence of malignant melanoma. J Cancer Res Clin Oncol. 1994; 120 Suppl: S32-34.
30. Li P, Yang R and Gao WQ. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer. 2014; 13: 55.
31. Jin JK, Dayyani F and Gallick GE. Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer. 2011; 128: 2545-2561.
32. Yoshida J, Horiuchi A, Kikuchi N, Hayashi A, Osada R, Ohira S, Shiozawa T and Konishi I. Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med Mol Morphol. 2009; 42: 82-91.
33. Xu J, Lamouille S and Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009; 19: 156-172.
34. Garzon R, Marcucci G and Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9: 775-789.
35. Huang S, He X, Ding J, Liang L, Zhao Y, Zhang Z, Yao X, Pan Z, Zhang P, Li J, Wan D and Gu J. Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer. 2008; 123: 972-978.
36. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, Caldeira J, Costa AM, Simoes-Correia J, Oliveira MJ, Pinheiro H, Pinho SS, Mateus R et al. Epithelial E-and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta. 2012; 1826: 297-311.
37. Hemavathy K, Ashraf SI and Ip YT. Snail/slug family of repressors: slowly going into the fast lane of development and cancer. Gene. 2000; 257: 1-12.
38. Wang Y, Shi J, Chai K, Ying X and Zhou BP. The Role of Snail in EMT and Tumorigenesis. Curr Cancer Drug Targets. 2013; 13: 963-972.
39. Smith BN and Odero-Marah VA. The role of Snail in prostate cancer. Cell Adh Migr. 2012; 6: 433-441.
40. Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS and Wu KJ. Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax. 2009; 64: 1082-1089.
41. Wilkes MC, Mitchell H, Penheiter SG, Dore JJ, Suzuki K, Edens M, Sharma DK, Pagano RE and Leof EB. Transforming growth factor-beta activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res. 2005; 65: 10431-10440.
42. Derynck R and Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425: 577-584.
43. Liu ZC, Wang HS, Zhang G, Liu H, Chen XH, Zhang F, Chen DY, Cai SH and Du J. AKT/GSK-3beta regulates stability and transcription of snail which is crucial for bFGF-induced epithelial-mesenchymal transition of prostate cancer cells. Biochim Biophys Acta. 2014; 1840: 3096-3105.
44. Vo BT, Morton D, Jr., Komaragiri S, Millena AC, Leath C and Khan SA. TGF-beta effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology. 2013; 154: 1768-1779.
45. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008; 10: 593-601.
46. Korpal M, Lee ES, Hu G and Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008; 283: 14910-14914.
47. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J. et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010; 12: 247-256.
48. Chhabra R, Dubey R and Saini N. Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases. Mol Cancer. 2010; 9: 232.
49. Zhu LH, Liu T, Tang H, Tian RQ, Su C, Liu M and Li X. MicroRNA-23a promotes the growth of gastric adenocarcinoma cell line MGC803 and downregulates interleukin-6 receptor. FEBS J. 2010; 277: 3726-3734.
50. Hu X, Chen D, Cui Y, Li Z and Huang J. Targeting microRNA-23a to inhibit glioma cell invasion via HOXD10. Sci Rep. 2013; 3: 3423.
51. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME and Hart IR. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res. 1984; 44: 3522-3529.
52. Ho ML, Hsieh YS, Chen JY, Chen KS, Chen JJ, Kuo WH, Lin SJ and Chen PN. Antimetastatic Potentials of Dioscorea nipponica on Melanoma In Vitro and In Vivo. Evid Based Complement Alternat Med. 2011; 2011: 507920.
53. Yu YH, Chen HA, Chen PS, Cheng YJ, Hsu WH, Chang YW, Chen YH, Jan Y, Hsiao M, Chang TY, Liu YH, Jeng YM, Wu CH et al. MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene. 2013; 32: 431-443.
54. Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, Shiah SG, Chen PS, Jeng YM, Cheng TY, Lai TC, Chang JS, Jan YH et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res. 2010; 70: 7830-7840.